Advertisement
CVM vs CYTK
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVM is a Hold and CYTK is a Hold.
CVM's RSI Oscillator leaves overbought zone
The 10-day RSI Oscillator for CVM moved out of overbought territory on October 07, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In 22 of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CVM as a result. In 90 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CVM turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 41 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CVM broke above its upper Bollinger Band on September 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +18.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVM advanced for three days, in 176 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 52 of 60 cases where CVM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 37 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. CVM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.729) is normal, around the industry mean (26.782). P/E Ratio (0.330) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.370) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CYTK's Indicator enters downward trend
The Aroon Indicator for CYTK entered a downward trend on October 13, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 161 similar instances where the Aroon Indicator formed such a pattern. In 137 of the 161 cases the stock moved lower. This puts the odds of a downward move at 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CYTK as a result. In 82 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYTK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for CYTK's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 69 cases where CYTK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for CYTK just turned positive on October 13, 2026. Looking at past instances where CYTK's MACD turned positive, the stock continued to rise in 43 of 57 cases over the following month. The odds of a continued upward trend are 75%.
Following a +2.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYTK advanced for three days, in 218 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
CYTK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. CYTK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 76 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYTK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (60.606) is normal, around the industry mean (26.782). CYTK's P/E Ratio (702.500) is considerably higher than the industry average of (43.395). CYTK's Projected Growth (PEG Ratio) (82.230) is slightly higher than the industry average of (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (437.542).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
CVM | CYTK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 39 | 68 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 97 Overvalued | 100 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 76 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 46 | 63 | |
P/E GROWTH RATING 1..100 | 37 | 1 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CVM's Valuation (97) in the Biotechnology industry is in the same range as CYTK (100). This means that CVM’s stock grew similarly to CYTK’s over the last 12 months.
CYTK's Profit vs Risk Rating (76) in the Biotechnology industry is in the same range as CVM (100). This means that CYTK’s stock grew similarly to CVM’s over the last 12 months.
CYTK's SMR Rating (100) in the Biotechnology industry is in the same range as CVM (100). This means that CYTK’s stock grew similarly to CVM’s over the last 12 months.
CVM's Price Growth Rating (46) in the Biotechnology industry is in the same range as CYTK (63). This means that CVM’s stock grew similarly to CYTK’s over the last 12 months.
CYTK's P/E Growth Rating (1) in the Biotechnology industry is somewhat better than the same rating for CVM (37). This means that CYTK’s stock grew somewhat faster than CVM’s over the last 12 months.
| CVM | CYTK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 71% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 84% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 75% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 71% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 76% |
| Advances ODDS (%) | 9 days ago 79% | 6 days ago 73% |
| Declines ODDS (%) | 2 days ago 90% | 2 days ago 78% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CVM’s FA Score shows that 0 FA rating(s) are green while CYTK’s FA Score has 1 green FA rating(s).
- CVM’s FA Score: 0 green, 5 red.
- CYTK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CVM’s TA Score shows that 3 TA indicator(s) are bullish while CYTK’s TA Score has 5 bullish TA indicator(s).
- CVM’s TA Score: 3 bullish, 5 bearish.
- CYTK’s TA Score: 5 bullish, 3 bearish.
Price Growth
CVM (@Biotechnology) experienced а -36.13% price change this week, while CYTK (@Biotechnology) price change was +0.44% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.49%. For the same industry, the average monthly price growth was -19.00%, and the average quarterly price growth was -19.88%.
Reported Earning Dates
CVM is expected to report earnings on Dec 23, 2026.
CYTK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Biotechnology (-8.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PEO | 29.47 | 0.29 | +0.99% |
| Adams Natural Resources Fund | |||
| GVLU | 27.80 | 0.16 | +0.58% |
| Gotham 1000 Value ETF (GVLU) | |||
| VBR | 235.62 | 0.91 | +0.39% |
| Vanguard Morningstar Small-Cap Value ETF (VBR) | |||
| MXE | 12.74 | 0.03 | +0.27% |
| Mexico Equity and Income Fund (The) | |||
| HELS | 24.34 | -0.01 | -0.03% |
| Hedgeye 130/30 Equity ETF (HELS) | |||